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SUMMARY
Background
The nonselective 5-HT4 receptor agonists, cisapride and tegaserod have been
associated with cardiovascular adverse events (AEs).
Aim
To perform a systematic review of the safety proﬁle, particularly cardiovascular,
of 5-HT4 agonists developed for gastrointestinal disorders, and a nonsystematic
summary of their pharmacology and clinical efﬁcacy.
Methods
Articles reporting data on cisapride, clebopride, prucalopride, mosapride, renza-
pride, tegaserod, TD-5108 (velusetrag) and ATI-7505 (naronapride) were identi-
ﬁed through a systematic search of the Cochrane Library, Medline, Embase and
Toxﬁle. Abstracts from UEGW 2006–2008 and DDW 2008–2010 were searched
for these drug names, and pharmaceutical companies approached to provide
unpublished data.
Results
Retrieved articles on pharmacokinetics, human pharmacodynamics and clinical
data with these 5-HT4 agonists, are reviewed and summarised nonsystematically.
Articles relating to cardiac safety and tolerability of these agents, including any
relevant case reports, are reported systematically. Two nonselective 5-HT4 agon-
ists had reports of cardiovascular AEs: cisapride (QT prolongation) and tegaserod
(ischaemia). Interactions with, respectively, the hERG cardiac potassium channel
and 5-HT1 receptor subtypes have been suggested to account for these effects. No
cardiovascular safety concerns were reported for the newer, selective 5-HT4 agon-
ists prucalopride, velusetrag, naronapride, or for nonselective 5-HT4 agonists with
no hERG or 5-HT1 afﬁnity (renzapride, clebopride, mosapride).
Conclusions
5-HT4 agonists for GI disorders differ in chemical structure and selectivity for
5-HT4 receptors. Selectivity for 5-HT4 over non-5-HT4 receptors may inﬂuence
the agent's safety and overall risk–beneﬁt proﬁle. Based on available evidence,
highly selective 5-HT4 agonists may offer improved safety to treat patients with
impaired GI motility.
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INTRODUCTION
Disorders of gastrointestinal (GI) motility are considered
a major pathophysiological mechanism underlying symp-
toms of functional GI disorders.1 Therapeutic agents have
been designed to stimulate muscle activity to address the
underlying hypomotility associated with disorders such as
slow-transit constipation, gastroparesis and ineffective
oesophageal motility.1 Activation of 5-HT4 receptors on
cholinergic nerve endings in the enteric nervous system
enhances the release of acetylcholine from motor neu-
rons, thereby stimulating GI propulsive motility.2, 3 From
these pharmacological observations, 5-HT4 receptor ag-
onists have been developed for the treatment of hypomo-
tility disorders. Nonselective 5-HT4 receptor agonists
such as cisapride and tegaserod were successfully devel-
oped for the treatment of hypomotility disorders of the
upper and lower GI tract, respectively.4, 5 Although both
drugs saw broad clinical use, they were associated with
cardiovascular adverse events (AEs).6–8 Cisapride was
subsequently withdrawn from the global market in 2000
and, since 2009, tegaserod, which never received approval
in the European Union (EU), has been limited to emer-
gency use in the United States.9, 10 These cardiovascular
AEs, which may be more related to a lack of selectivity of
certain compounds or classes of compounds, rather than
to genuine 5-HT4 receptor-mediated effects, have strongly
impacted the perceived risk–beneﬁt ratio of 5-HT4 recep-
tor agonists. Meanwhile, a newer generation of selective
5-HT4 receptor agonists is being developed for the treat-
ment of GI motility disorders. In this article, we review
the safety proﬁle of older and newer 5-HT4 receptor ag-
onists developed for GI disorders, focusing on their car-
diovascular risk proﬁle.
PHARMACOLOGY OF 5-HT4 RECEPTOR AGONISTS
Structure of 5-HT4 receptors
5-HT4 receptors are heptahelical receptors, which pri-
marily couple to the stimulatory protein Gs and activate
the 3′,5′ cyclic adenosine monophosphate-dependent
protein kinase A pathway.11, 12 Most of the 5-HT4 recep-
tor splice variants are identical up to leucine 358, but
their intracellular C-terminal tails differ.13 The splice
variants 5-HT4(a) and 5-HT4(b) have been found in all
species studied thus far, with 5-HT4(b) being the domi-
nant splice variant in human tissues.14 Additional splice
variants have also been identiﬁed in human (h5-HT4(c),
h5-HT4(d), h5-HT4(g), h5-HT4(i) and h5-HT4(n)), mouse
(m5-HT4(e) and m5-HT4(f)) and rat (r5-HT4(c1) and r5-
HT4(e))
13, 15, 16 and more recently in porcine tissue.17
The physiological implication of the multitude of splice
variants and their differential coupling to signal trans-
duction cascades remains unclear.
Furthermore, several observations suggest that there is
cell type-, tissue-speciﬁc or disease-state-speciﬁc expres-
sion (e.g. in gastroparesis) of certain splice vari-
ants.13, 18–21 However, currently, there are no drugs
which reliably discriminate among 5-HT4 receptor splice
variants, but such drugs could provide an interesting
alternative opportunity for tissue-speciﬁc drug targeting.
Tissue distribution of 5-HT4 receptors
5-HT4 receptors are localised to neurons in the central
nervous system, including the prefrontal cortex,22, 23 hip-
pocampus12, 22 and mesolimbic and nigrostriatal dopa-
mine systems.24 Functional 5-HT4 receptors are also
found in the GI tract, bladder and heart.3, 25, 26
In the GI tract, 5-HT4 receptors are expressed in
enteric neurons27 as well as smooth muscle cells.28–30 As
a major consequence of 5-HT4 receptor activation, ace-
tylcholine is released from interneurons and motor neu-
rons, thus increasing propulsive motility.30–37
Classes of 5-HT4 receptor agonists
Several different classes of 5-HT4 receptor agonists have
been developed for the treatment of GI disorders. We
review those classes here, focusing on their afﬁnity and
selectivity for the 5-HT4 receptor, as well as any tissue-
dependent agonism (partial or full agonism) that might
arise (in part) from differences in receptor reserve or
coupling efﬁciency between different tissues.38 Whether
or not a drug is a full or partial agonist in a given tissue
may depend on the receptor concentration or the efﬁ-
ciency of the receptor-effector coupling. Thus, it may be
feasible to obtain a certain degree of tissue selectivity
with a low efﬁcacy agonist or low doses of a high efﬁ-
cacy agonist (in favour of tissues with high receptor
reserve for the given agonist, such as the GI tract), as tis-
sues with no receptor reserve for the agonist would not
be stimulated by this drug.
Benzamides. The substituted benzamides, including
metoclopramide, cisapride, renzapride, mosapride, clebo-
pride and naronapride (ATI-7505) are 5-HT4 receptor
agonists with moderate afﬁnity and poor selectivity for
the 5-HT4 receptor (Figure 1).
2 Metoclopramide is also
an antagonist at D2 dopamine receptors and at 5-HT3
receptors, while cisapride blocks 5-HT2 and 5-HT3
receptors and the human ether-a-go-go-related gene
(hERG)-encoded K+ channel.39, 40 The consequences of
746 Aliment Pharmacol Ther 2012; 35: 745-767
ª 2012 Blackwell Publishing Ltd
J. Tack et al.
these interactions are clearer for some than for others;
for example, the prolongation of cardiac action potential
repolarisation and, thus, QT (the time elapsing from the
beginning of the QRS complex to the end of the T wave
in an electrocardiogram) interval, due to the blockade of
the hERG channel by cisapride, is likely to underlie the
arrhythmogenic potential of this nonselective 5-HT4
receptor agonist.7, 41 These non-5-HT4 receptor sites of
action, coupled with their tissue-dependent pharmacody-
namics, complicate the description of the actions of ben-
zamides in vivo.
In the rat oesophagus, 5-HT4 receptors are localised
to the muscularis mucosae (smooth muscle), where they
mediate relaxation. In this tissue, cisapride, renzapride
and mosapride have 80–90% of the intrinsic activity of
5-HT.28, 42 In the guinea-pig distal colon, cisapride, ren-
zapride and mosapride mediate a contractile response
and have 80–100% of the intrinsic activity of 5-HT.43
Therefore, in both the guinea pig colon and rat oesopha-
gus, benzamides are full agonists. In contrast, in the gui-
nea pig ileum, cisapride, renzapride and mosapride have
only 50–60% of the intrinsic activity of 5-HT.32, 42 Simi-
larly, cisapride has <60% of the intrinsic activity of 5-HT
in relaxing circular muscle strips of the canine rectum.29
Little preclinical information is available on narona-
pride, another substituted benzamide 5-HT4 receptor
agonist designed to have the same therapeutic beneﬁt as
cisapride, but without the side effects. Naronapride is
structurally similar, but more selective, than cisapride,
with minimal hERG channel activity as well as minimal-
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Figure 1 | Molecular structure of 5-HT4 agonists.
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to-no activity at 5-HT3 receptors.
44 Naronapride stimu-
lates GI motility in vivo in dogs45 and in humans.44
Carbazimidamides. Tegaserod is an indole carbazimida-
mide agonist with high afﬁnity for the 5-HT4 receptor,
but it is also a 5-HT2(a) and 5-HT2(b) receptor antagonist
and 5-HT1 receptor agonist (Figure 1).
27, 46, 47 The con-
tribution of 5-HT2B receptor antagonism to the thera-
peutic actions of tegaserod on gut motility remains
unknown. Early studies showed that tegaserod facilitates
the peristaltic reﬂex in vitro in human small intestine,
and guinea pig and rat colonic preparations.48 When
agonist-evoked contractions of the guinea pig ileum were
studied, tegaserod was equipotent with 5-HT, but had
only 30% of the intrinsic activity of 5-HT.49, 50 In vitro
studies comparing 5-HT4 receptor-mediated relaxation of
canine rectal smooth muscle showed that tegaserod was
10-fold less potent than 5-HT and had only 55% of the
intrinsic activity of 5-HT.29 In the porcine stomach, te-
gaserod had approximately the same intrinsic activity as
5-HT when increases in cholinergic neurogenic contrac-
tions were measured.38 These data indicate that tegas-
erod is a potent 5-HT4 receptor agonist in all tissues
tested. While tegaserod is frequently identiﬁed as a par-
tial receptor agonist, this property is tissue-depen-
dent.27, 38
Benzofurancarboxamides. Prucalopride belongs to the
class of benzofurancarboxamide agonists, which have
high afﬁnity and selectivity for the 5-HT4 receptor, and
tissue-speciﬁc agonist activity (Figure 1).27, 38 The most
pronounced effect of prucalopride is stimulation of colo-
nic motility.51–53 Prucalopride is 10-fold less potent than
5-HT in causing relaxation of canine rectum circular
muscle, with 82% of the intrinsic activity of 5-HT.29 In
guinea pig colon, prucalopride is approximately 10-fold
less potent than 5-HT in stimulating peristalsis, but was
equally effective as 5-HT (i.e. the maximal effect reached
at high concentrations is similar to that of 5-HT) in this
assay.54 In vivo, prucalopride dose-dependently stimu-
lated high-amplitude clustered contractions in the proxi-
mal colon and inhibited contractile activity in the distal
colon.52 Prucalopride also induced giant migrating con-
tractions, the canine equivalent of mass movements.52
Other agonists. Velusetrag (TD-5108) is a dihydroquin-
oline-carboxylic acid derivative that has high afﬁnity and
selectivity for 5-HT4 receptors in a number of in vitro
assays, and is an effective stimulant of GI motility in
vivo (Figure 1). Velusetrag has comparable intrinsic
activity with 5-HT in the guinea pig colon and rat
oesophagus tunica muscularis mucosa preparations, and
has little or no activity at heterologously-expressed
sodium channels or potassium channels.55 Velusetrag is
more potent than tegaserod, cisapride and mosapride at
stimulating colonic transit in conscious guinea pigs, and
approximately equipotent with tegaserod at stimulating
small intestinal motility in conscious dogs or relaxing
the oesophagus in anaesthetised rats.56
Several other 5-HT4 receptor agonists have been
developed for use in GI disorders, but development has
ceased or limited data are available, so they will not be
reviewed here. These agents include cinitapride
(LAS17177), lintopride (STIL 2875), lirexapride
(JL17454/CHF17454), PF885706 and E3620.
Conclusions on pharmacology of 5-HT4 agonists
5-HT4 receptors are a widely expressed and dynamic
class of receptors and 5-HT4 receptor agonists are effec-
tive stimulants of GI motility. Differences in the pharma-
cology of 5-HT4 receptor agonists originates mainly
from differences in their selectivity for 5-HT4 over other
receptor types, such as 5-HT1 and 5-HT2 receptors, and
the hERG channel (Table 1), or by their degree of tis-
sue-speciﬁc agonism.
METHODS
The purpose of this review was to comprehensively
search and systematically review the evidence on the
safety of 5-HT4 receptor agonists developed for GI disor-
Table 1 | Receptor binding proﬁle of 5-HT4 agonists
for GI disorders, at therapeutic concentrations
Drug
Receptor binding proﬁle at therapeutic
concentrations
5-HT4 5-HT3 5-HT2 5-HT1 D2 hERG
Cisapride + + + +
Tegaserod + + + +
Renzapride + +
Clebopride + + +
Mosapride + +
Prucalopride +
Velusetrag +
Naronapride +
GI, gastrointestinal.
+ indicates afﬁnity for this receptor (as either agonist or
antagonist) that is likely to be clinically relevant at concentra-
tions necessary for 5-HT4 agonism (i.e. for therapeutic action).
Information from De Maeyer et al.27
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ders, with particular reference to cardiovascular safety.
Literature on pharmacokinetics, human pharmacody-
namics and clinical data was also collected systematically,
but summarised nonsystematically and therefore not pre-
sented here in full.
An independent researcher at the Royal Society of
Medicine Library Search Services performed a compre-
hensive search of the Cochrane Library (including the
Cochrane Database of Systematic Reviews, the Database
of Abstracts of Reviews of Effects, the Cochrane Central
Register of Controlled Trials, the Health Technology
Assessment Database and the NHS Economic Evaluation
Database), Medline (1949 – April 2009), Embase (1974 –
April 2009) and ToxFile (1900 – April 2009) in June
2009. The search encompassed all types of clinical trials
as well as systematic reviews, meta-analyses and case
reports, using the terms ‘cisapride’ OR ‘clebopride’ OR
‘prucalopride’ OR ‘mosapride’ OR ‘renzapride’ OR ‘tegas-
erod’ OR ‘TD-5108’ OR ‘ATI-7505’, including derivatives
of these terms and other names used for these drugs.
Limits applied were: English language, humans and
adults. No date limitation was imposed. The searches
were repeated in June 2010 to identify any new reports
that emerged during the time taken to develop the man-
uscript. Upon revision of the manuscript in December
2011, an additional search for pharmacokinetic informa-
tion was conducted and relevant references were
obtained. Authors also contacted the medical informa-
tion departments of relevant pharmaceutical companies
to request further unpublished information or abstracts
presented at conferences. The reference lists of retrieved
articles were also reviewed.
Abstracts presented at UEGW 2006–2008 and at DDW
2008–2010 (i.e. for all years where abstracts were search-
able electronically) were also searched by medical writing
support staff, for mention of the drugs of interest (listed
above), and those reporting data not already published in
the retrieved articles were included in the analysis.
The Royal Society of Medicine use an automated
duplicate checker, followed by hand-screening by the
researcher to remove duplicates before records were
reviewed. The remaining abstracts were ﬁltered for rele-
vance according to predeﬁned eligibility criteria: studies
had to relate to GI disorders, to the study drug (listed
above), be either clinical studies or systematic reviews
(including meta-analyses) and case reports were only
included if they related to cardiac safety. Resulting
abstracts were then hand-searched against the same eligi-
bility criteria by a second reviewer, and relevant abstracts
were segregated into pharmacokinetics, human pharma-
codynamics, clinical studies and safety/tolerability, and
full-text of these articles obtained. Full text was then
reviewed independently by the authors. Cardiac-related
safety/tolerability information was systematically
reviewed and data retrieved from the full text by the
authors were included in the manuscript, as the study
authors had originally reported (without using any spe-
ciﬁc summary measures or additional analyses). Any dis-
crepancies were discussed with the authors. No speciﬁc
form was used to extract data, risk of bias of individual
studies was not formally assessed and data from individ-
ual studies were not combined.
RESULTS
The literature searches, after removal of duplicates,
returned a total of 1164 articles. A total of 61 conference
abstracts were identiﬁed.
The original cisapride search returned 582 articles. Of
these, 381 were selected for full-text review (20 pharma-
cokinetic, 141 pharmacodynamic, 183 clinical efﬁcacy, 37
safety). Of these, 75 were considered relevant and cited
in this article; 31 additional articles were identiﬁed and
included. In the 2010 update to the search, four articles
were identiﬁed, two of which met inclusion criteria.
None of the three conference abstracts identiﬁed were
considered relevant.
The tegaserod search returned 162 articles in the ori-
ginal search, and 13 in the update. Of these, 100 were
selected for full-text review and 22 were considered rele-
vant and cited in this article; nine additional articles
were identiﬁed and included. Upon revision of the man-
uscript in 2011, one additional article was identiﬁed in
the search and included in the manuscript. None of the
19 conference abstracts identiﬁed was included in this
report.
The renzapride search returned 105 articles in the ori-
ginal search and two in the update. Of these, 17 were
selected for full-text review and seven were considered
relevant and cited in this article; two additional articles
were identiﬁed and included. Upon revision of the man-
uscript in 2011, one additional article was identiﬁed in
the search and included in the manuscript. No renza-
pride conference abstracts were identiﬁed.
The clebopride search returned 58 results, of which 38
were selected for full-text review. Of these, eight were
included in this report (two of these were originally
excluded for not meeting inclusion criteria, but provided
useful supporting information so were included by the
author). Of the 16 safety-related articles selected for full-
text review, none related to cardiac safety; two represen-
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tative articles (movement disorders) were included in
this report. Four additional articles, as well as the
clebopride prescribing information and an in vitro report
were identiﬁed and included. Upon revision of the man-
uscript in 2011, three additional articles were identiﬁed
in the search and included in the manuscript. No clebo-
pride conference abstracts were identiﬁed.
The original mosapride search identiﬁed 120 results,
and the second search an additional four items. Of these,
41 were selected for full-text review (including three arti-
cles relating to safety). Sixteen were selected to report
here, including the two relevant safety reports. An addi-
tional seven reports were identiﬁed through other
sources and included, as well as six background articles
(including the mosapride prescribing information). Upon
revision of the manuscript in 2011, one additional article
was identiﬁed in the search and included in the manu-
script. None of the 17 mosapride conference abstracts
identiﬁed were included in this report.
The prucalopride search returned 121 articles in the
original search, and seven in the update. Of these, 32
were selected for full-text review and 16 considered rele-
vant and cited in this article; four additional articles were
identiﬁed and included. Of the 20 conference abstracts
identiﬁed, ﬁve presented relevant information from stud-
ies not already covered by full publications, so were
included in this report. One related to cardiac safety.
The ATI-7505 search returned 11 articles in the origi-
nal search and one in the update. Of these, one was
selected for full-text review and one considered relevant
and cited in this article; four additional articles were
identiﬁed and included. Upon revision of the manuscript
in 2011, one additional article was identiﬁed in the
search and included in the manuscript. No conference
abstracts were identiﬁed.
The TDI-5108 search returned ﬁve articles in the ori-
ginal search and three in the update. Of these, three were
selected for full-text review and two considered relevant
and cited in this article; two additional articles were
identiﬁed and included. Two conference abstracts were
identiﬁed and included in this report.
Nonselective 5-HT4 receptor agonists
Historically, metoclopramide was the ﬁrst 5-HT4 recep-
tor agonist to be used for the treatment of hypomotility
disorders. The drug is also a D2 receptor antagonist, an
action which underlies the well-established, potentially
irreversible, neurological side effects that may occur with
metoclopramide intake,57 and therefore will not be
described in detail.
Cisapride. Cisapride, an agonist at 5-HT4 receptors and
an antagonist at 5-HT3 and 5-HT2 receptors, was intro-
duced worldwide in the 1990s, and has widespread
prokinetic effects throughout the GI tract. Although orig-
inally employed in a wide range of motility disorders,
cisapride was approved for the treatment of acute and
severe exacerbations of demonstrated chronic idiopathic
or diabetic gastroparesis after failure of other treatment
options in the EU, and was approved by the U.S. Food
and Drug Administration (FDA) for nocturnal heartburn
only.
Pharmacokinetics and pharmacodynamics. The pharma-
cokinetics and pharmacodynamics of cisapride are sum-
marised in Tables 2 and 3 respectively.
Clinical trials. Clinical trials, summarised in Supplemen-
tary Table S1, have explored the efﬁcacy of cisapride in a
number of GI conditions, including GERD, functional
dyspepsia, gastroparesis, chronic intestinal pseudo-
obstruction, post-operative ileus and chronic constipa-
tion, but evidence of an effect was not robust enough to
obtain regulatory approval for indications other than
nocturnal heartburn. In 2000, cisapride was withdrawn
from the market worldwide, due to concerns over car-
diovascular safety (see safety and tolerability section).
Safety and tolerability. Initial experience with cisapride,
including post-marketing data from two study popula-
tions totalling over 23 000 patients, suggested that the
drug was remarkably safe, with diarrhoea (incidence
4.1%), abdominal pain (1.6%), nausea or vomiting
(1.5%), headache (1.4%) and constipation (1.2%) being
the most frequently reported AEs.58 In an epidemiologi-
cal study of almost 37 000 patients prescribed cisapride
in the UK and Canada, serious cardiac rhythm disorders
were not found to be inordinately associated with cisa-
pride use; however, the 95% conﬁdence interval was
large (0.2–9.8), such that an increase in risk could not be
ruled out deﬁnitively.59 In children without underlying
cardiac disease or electrolyte imbalance, cisapride was
found to have no signiﬁcant effect on cardiac electrical
function,60 and a meta-analysis of randomised, con-
trolled clinical trials among children with GERD found
that although there was no evidence of adverse or harm-
ful events, there were no signiﬁcant clinical beneﬁts.61
Reports of cardiac events began to accumulate, includ-
ing palpitations62 and instances of an unusual tachyar-
rhythmia, torsades de pointes, as well as ventricular
ﬁbrillation and sudden death started to appear.63 It soon
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came to be recognised that cisapride use could result in
prolongation of the QT interval and, thereby, increase
the risk of arrhythmia, a phenomenon well described in
association with a number of other drugs, most notably
quinidine, but including procainamide, sotalol, amioda-
rone, disopyramide, macrolide antibiotics (including
erythromycin), astemizole, terfenadine, phenothiazines
and tricyclic antidepressants. An increased risk was pres-
ent when cisapride levels were higher, e.g. through con-
comitant use of CYP450 inhibitors. Indeed, the majority
of cardiac AEs occurred when cisapride was used in
patients with other risk factors, which included co-
administration with other drugs (e.g. triazole antifungals
and retrovirals) and foods such as grapefruit juice,64
which inhibit hepatic cytochrome (CYP) P450 3A4
resulting in high plasma levels of cisapride, or that also
caused QT prolongation, as listed above. It also became
clear that the likelihood of arrhythmia in association
with cisapride use was greater among those with serious
underlying disease states such as heart disease, heart fail-
ure, respiratory failure, renal failure, hypokalaemia or
hypomagnesaemia.
Subsequently, the cellular and molecular basis for the
arrhythmogenic potential of cisapride was revealed. In vi-
tro studies found cisapride to be a potent and dose-
dependent blocker of the hERG channel,41 which is the
main channel responsible for the repolarisation phase of
the cardiac action potential,7 such that hERG blockade
(or channel mutations) prolong the duration of the
action potential by delaying the repolarisation phase.65
Other studies suggested that it was not QT prolongation
per se, but rather, the increase in dispersion of repolari-
sation that usually accompanies QT prolongation, which
provides the arrhythmogenic substrate.66
Although some studies suggested that cisapride had a
low arrhythmogenic potential among neonates regardless
of gestational age,67 others drew attention to the low lev-
els of CYP 3A4 in the neonatal liver68 and the conse-
quent effects on cisapride metabolism. Indeed, a
pharmacokinetic study in premature infants demon-
strated increased serum concentrations of cisapride and
parallel prolongations of the QT interval.69
Unfortunately, around the same time, the prokinetic
properties of erythromycin had begun to be widely
appreciated and its co-administration with cisapride, or
the sequential use of i.v. erythromycin and oral cisapride,
was not uncommon; thus, increasing the potential for
QT prolongation, through its own effects on the QT
interval as well as through its inhibition of CYP450.70–72
Others at risk were those with congenital prolongation
of the QT interval, a family history of the long QT syn-
drome or those with signiﬁcant bradycardia.
As large surveys in adults, children and neonates had
indicated that such events were rare58, 73–76 and that
risks could be managed by an appropriate awareness
programme, the initial response was a risk management
programme identifying those at risk, as well as drugs
that should not be co-administered with cisapride.
Accordingly, in 1995, a ‘black box’ warning contraindi-
cating the use of cisapride among those taking drugs that
affected its metabolism was issued by the FDA. At that
time, 34 cases of torsades de pointes, 23 of prolonged
QT interval and 4 deaths had been reported.63 In 1996,
further warnings were issued in relation to concomitant
medications that also prolonged the QT interval and in
conditions that predisposed to cardiac arrhythmias. As a
result, the ‘black box’ was expanded in 1998. However,
the subsequent realisation that serious cardiac AEs could
occur among low-risk groups, including children, cou-
pled with the documentation of continued cisapride use
in contraindicated situations8 led to the commercial,
worldwide withdrawal of the drug in July 2000.
Tegaserod. Tegaserod is a 5-HT4 receptor agonist with a
high afﬁnity for 5-HT4 receptors, but also relevant afﬁnity
for 5-HT2(a/b), and 5-HT1(a/b/d) receptors.
27, 77 Tegaserod
was approved in many countries for the treatment of IBS-
C and chronic idiopathic constipation. In March 2007, te-
gaserod was withdrawn from most markets owing to an
increased risk of cardiovascular AEs. It was reintroduced
in the USA in July 2007 under a treatment investigational
new drug protocol for IBS-C and chronic idiopathic con-
stipation in women younger than 55 who are not at risk
for certain cardiovascular events. Tegaserod was not
approved for use in the EU as the Committee for Medici-
nal Products for Human Use was of the opinion that the
beneﬁt of tegaserod treatment did not outweigh its risks.
Pharmacokinetics and pharmacodynamics. The pharma-
cokinetics and pharmacodynamics of tegaserod are sum-
marised in Tables 2 and 3 respectively.
Clinical studies. While the beneﬁt of tegaserod therapy
in patients with IBS-C has been fairly well demonstrated,
evidence of efﬁcacy in chronic idiopathic constipation
and functional dyspepsia has been less convincing (sum-
marised in Supplementary Table S2).
Safety and tolerability. The frequency of reported AEs
in the 3-month trials with tegaserod varies considerably
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(e.g. 50–60% of US patients reported AEs),78 whereas
only 4% of the patients in an Asia-Paciﬁc trial79 and
38% (13% drug-related) in a European trial did so.80 As
this can be explained neither by different doses nor by
trial design, cultural differences in the willingness to
complain are the most likely explanation.
The most common AEs were diarrhoea, headache and
abdominal pain,78–81 and were graded as mild, sometimes
as moderate.80 Only diarrhoea was reproducibly more
prevalent in the tegaserod than in the placebo groups, but
this was not dose-related.78 Diarrhoea occurred mainly in
the ﬁrst week of treatment and was often transient, resolv-
ing with continued treatment.78 The safety proﬁle did not
change over a 12-month period with open treatment82:
headache became the most prevalent AE (10–15%); all
other AEs, in particular diarrhoea, ranged below 10%.
Three AEs potentially attributable to tegaserod have
gained particular attention, namely an increased rate of
abdominal surgery, ischaemic colitis and cardiac events.
They occurred so infrequently that they are unlikely to
be identiﬁed in Phase III trials and may only come up in
pooled analyses or during post-marketing surveillance,
but they are severe enough to warrant concerns.83
Regarding abdominal surgery in patients with IBS-C, a
meta-analysis of 13 controlled trials was conducted,
which found no signiﬁcant difference in the rates of
abdominal and pelvic surgery between patients receiving
tegaserod (0.44%) and those on placebo (0.41%).83
Patients with IBS have a higher risk of developing
colonic ischaemia than the general population.84 No
cases of ischaemic colitis occurred in over 11 600
patients participating in clinical trials with tegaserod.85
Although post-marketing reports have noted cases of is-
chaemic colitis86, 87 and intestinal ischaemia88 in patients
taking tegaserod, the incidence appears to be similar to
the general population and is less than estimates for the
IBS patient population.89 Moreover, no mechanism has
been identiﬁed through which tegaserod might predis-
pose to ischaemic colitis.
The pre-marketing data of systematic cardiac safety
assessment may be summarised as follows: in three
randomised, double-blind, controlled, parallel-group clin-
ical studies with more than 2500 IBS patients, prolonga-
tion of the QTc interval was similarly frequent between
groups, as was the frequency of overall electrocardio-
graphic abnormalities. No ventricular or supraventricular
tachycardia was observed. In healthy volunteers, tegas-
erod at i.v. doses resulting in plasma concentrations up to
100 times those measured after therapeutic doses (6 mg
b.d.) did not inﬂuence electrocardiographic variables.90
Data collected from over 18 000 patients demon-
strated cardiovascular AEs (myocardial infarction, unsta-
ble angina pectoris, stroke and one sudden death) in 13
of 11 614 patients treated with tegaserod (a rate of
0.11%) compared with 1 of 7031 patients treated with
placebo (a rate of 0.01%). Therefore, in 2007, the FDA
requested withdrawal from the market, citing a relation-
ship between prescriptions of the drug and increased
risks of heart attack or stroke. However, this was denied
by the manufacturer, as all affected patients were said to
have pre-existing cardiovascular disease or risk factors
for such.6 Thus, no causal relationship between tegaserod
use and cardiovascular events had been demonstrated.
Indeed, a matched case–control study of tegaserod-trea-
ted patients with untreated patients found no association
between tegaserod and adverse cardiovascular out-
comes.91
A hypothetical mechanism for tegaserod-related
cardiac events was proposed involving interaction at
5-HT1(b/d) receptors on coronary arterioles.
92 However,
as tegaserod does not behave as a 5-HT1(b) receptor ago-
nist in a recent study of human isolated proximal and
distal coronary arterioles, the mechanisms involved
remain unclear.93
Renzapride. Renzapride, a 5-HT4 receptor agonist and a
5-HT3 receptor antagonist,
94 has been evaluated in the
treatment of IBS-C, but has not been approved in any
part of the world.
Pharmacokinetics and pharmacodynamics. The pharma-
cokinetics and pharmacodynamics of renzapride are
summarised in Tables 2 and 3 respectively.
Clinical studies. Clinical studies with renzapride have
focused mainly on IBS (summarised in Supplementary
Table S3). However, therapeutic margins were only mini-
mal (5–6% over placebo), and this led to the discontinu-
ation of the drug development programme.95
Safety and tolerability. Renzapride was well tolerated;
most AEs were mild-to-moderate in intensity and
equally distributed across active or placebo treatment
groups. The most common AEs were GI, with diarrhoea
and abdominal pain being the most commonly associ-
ated with renzapride treatment.96–99
In vitro cardiac conductivity studies in isolated Pur-
kinje ﬁbres showed no signiﬁcant QT prolongation by
renzapride. In transfected cells, renzapride was a 1000-
fold less potent inhibitor of the hERG channel compared
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with cisapride.100 In the clinical trial programme, no sig-
niﬁcant ECG alterations were observed (in particular no
evidence of prolongation of the QT interval).95–99, 101
Clebopride. Clebopride is a D2 receptor antagonist, as
well as a 5-HT4 receptor agonist and a 5-HT3 receptor
antagonist.102 Clebopride is available in Italy and Spain
as a gastroprokinetic drug.
Pharmacokinetics and pharmacodynamics. The pharma-
cokinetics and pharmacodynamics of clebopride are
summarised in Tables 2 and 3 respectively.
Clinical studies. To our knowledge, the effects of clebo-
pride on lower GI motility and therapeutic potential in
lower GI indications have not been explored. Controlled
studies investigating the effects of clebopride have pri-
marily focused on FD, but are dated and are generally
underpowered with methodological ﬂaws compared with
current requirements of good clinical practice (summar-
ised in Supplementary Table S4).
Safety and tolerability. Antagonism of dopamine recep-
tors in the GI tract promotes coordinated motor activity
and accelerates transit, while blockade of D2 receptors in
the area postrema exerts an anti-nausea, anti-emetic
effect.103, 104 However, central D2 receptor blockade is
also responsible for AEs, including extrapyramidal dys-
tonic reactions and hyperprolactinaemia.105 Comparative
studies among prokinetics have demonstrated that clebo-
pride is most associated with dystonic reactions106, 107
that are not limited to reversible Parkinsonian-like symp-
toms, but also include tardive, potentially irreversible,
dyskinesia.108 The calculated prevalence of movement
disorders associated with chronic use of other antidop-
aminergics is around 1%,109 but it is 4-fold higher for
clebopride.110 Conversely, clebopride exerts a less pro-
nounced hyperprolactinaemic effect compared with any
other antidopaminergic drug.105
Substituted benzamides have been associated with
dose-dependent cardiac AEs. Thus, although overt car-
diotoxicity has not been reported in clinical studies on
clebopride, the effects of the drug on cardiac action
potential duration, hERG channel, and sodium channel
currents were investigated in vitro.111 Clebopride
(10 lM) prolonged the action potential duration at 90%
(but not 50%) repolarisation. Furthermore, an IC50 value
of 0.62 ± 0.30 lM for hERG channel currents was deter-
mined. No effect was observed on sodium channel cur-
rents.111 It was concluded that clebopride is sufﬁciently
safe at therapeutic doses, but overdosing or impaired
metabolism might be associated with torsadogenic
effects.
Mosapride. Mosapride is primarily a selective 5-HT4
receptor agonist in the GI tract.112–114 Its principal
metabolite is approximately 50% as potent as the parent
compound at stimulating gastric motility, however, it is
also a potent 5-HT3 receptor antagonist.
115 Mosapride is
available as a prokinetic agent in a number of Asian
countries.
Pharmacokinetics and pharmacodynamics. The pharma-
cokinetics and pharmacodynamics of mosapride are
summarised in Tables 2 and 3 respectively.
Clinical trials. Several studies have been performed to
assess the efﬁcacy of mosapride for the treatment of FD.
However, most studies were small and lack controls and,
as such, failed to show signiﬁcant symptomatic improve-
ments (summarised in Supplementary Table S5).116
Safety and tolerability. In contrast to cisapride, mosa-
pride does not appear to have any signiﬁcant effect on
K+ channels. Using isolated rabbit Purkinje ﬁbres and
ventricular muscle, mosapride had little effect on the
rapid component of the delayed rectifying K+ channels
and no effect in hERG transfected cells.39, 117, 118 Using
a rabbit model of the acquired long-QT syndrome, cisa-
pride prolonged the QT interval, while mosapride did
not,117 despite its metabolism by CYP3A4.119 In a 14-
day study of mosapride (15 mg/day) in 10 healthy male
volunteers, no ECG changes were noted despite co-
administration of erythromycin.120 In a separate study of
20 healthy volunteers who received a single dose of mo-
sapride (10 mg), pulse, heart rate, QT interval and ECGs
were no different after drug administration.121 Further-
more, in a study of 18 patients who were taking a variety
of psychiatric medications, co-administration of mosa-
pride did not change any ECG parameters.122 However,
a case report described a 68-year-old man with sick sinus
syndrome, requiring a permanent pacemaker and con-
comitant ﬂecainide therapy, who developed a prolonged
QTc interval after starting mosapride.123 In summary,
the studies published to date demonstrate that mosapride
is safe without any signiﬁcant cardiovascular effects.
Selective 5-HT4 receptor agonists
Prucalopride. Prucalopride is a dihydrobenzofurancarb-
oxamide derivative with distinct structural differences
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from other 5-HT4 receptor agonists such as cisapride
and tegaserod. These differences are likely to account for
the greater selectivity for the 5-HT4 receptor observed
with prucalopride (>1509 for prucalopride vs. <1 for
cisapride and tegaserod).124 Prucalopride was recently
approved, on 15 October 2009, by the European Medi-
cines Agency (EMA) for the symptomatic treatment of
chronic constipation in women in whom laxatives fail to
provide adequate relief.
Pharmacokinetics and pharmacodynamics. The pharma-
cokinetics and pharmacodynamics of prucalopride are
summarised in Tables 2 and 3 respectively.
Clinical trials. The majority of clinical studies with pru-
calopride were conducted in patients with chronic con-
stipation (summarised in Supplementary Table S6).
Multiple randomised, controlled trials found that prucal-
opride at doses of 1–4 mg (q.d.) improved symptoms of
chronic constipation, including stool frequency, stool
consistency, straining and quality of life.125–128
To date, no studies addressing the efﬁcacy of prucalo-
pride in the IBS-C or upper GI disorders, such as gastro-
paresis or FD, have been presented.
Safety and tolerability. Safety assessments were per-
formed as part of the Phase III studies.125, 127, 128 Treat-
ment-associated AEs were reported in 70–80% of
patients randomised to placebo, 2 or 4 mg of prucalo-
pride. The most common treatment-associated AEs
included headache in 25–30% of prucalopride subjects
vs. 12–17% of placebo; nausea (12–24% vs. 8–14%);
abdominal pain (16–23% vs. 11–19%); and diarrhoea
(12–19% vs. 3–5%). The majority of AEs occurred within
the ﬁrst 24 h of treatment and proved transient.
Pooled results of the three Phase III studies show that
serious AEs (SAEs) were reported in 2.7% of patients
receiving the recommended dose of 2 mg (n = 661) vs.
2.0% of patients receiving placebo (n = 659).129 Discon-
tinuation rates from AEs ranged from 4% to 15% among
patients receiving prucalopride and from 2% to 7%
among patients receiving placebo. Many discontinuations
were the consequence of headache, abdominal pain, nau-
sea, vomiting or diarrhoea which occurred on the ﬁrst
day of study drug administration.
Data from an open-label, long-term extension trial
were recently reported.130 In this study, 1775 constipated
patients who had completed one of the Phase III studies
were followed up for a mean of 231 days (range 1–
721 days). Similar to the Phase III trials, the most com-
mon AEs were headache (31%), abdominal pain (24%),
diarrhoea (20%), ﬂatulence (16%) and nausea (15%). The
most common AE rated as ‘severe’ was surgical interven-
tion (3.3%). SAEs were uncommon (<0.5%). The most
common AEs leading to discontinuation were abdominal
pain (1.5%) and headache (1.5%). Two deaths occurred;
one was deemed unrelated to prucalopride and no treat-
ment information was available for the other.130
Unlike other 5-HT4 receptor agonists, prucalopride has
not been found to interact with the hERG channel or 5-
HT1(b) receptors, each postulated to be responsible for
the development of adverse cardiovascular effects with
other 5-HT4 receptor agonists.
39, 92 Cardiovascular safety
was evaluated in two Phase I, double-blind, controlled,
two-way cross-over studies which included 32 and 24
healthy volunteers, in which prucalopride was escalated
to a maximum dose of either 10 or 20 mg.131 No clini-
cally relevant differences in blood pressure or incidence
of prolonged QTc were identiﬁed between groups. Simi-
larly, no correlation was found between observed shifts in
ECG parameters based upon prucalopride concentrations
up to 10 times the recommended therapeutic dose. A
small, transient increase in mean heart rate and associ-
ated decrease in the PQ and QT intervals was observed
with prucalopride. Within-subject differences between the
groups were not statistically different. Cardiovascular
safety was also carefully assessed in the Phase III clinical
trials. There were no differences in vital signs or ECG
parameters between study participants randomised to
placebo or either dose of prucalopride. The incidence of
QT interval prolongation (>470 ms) was low ( 2.1%)
and similar between groups.125, 127, 128 A single cardio-
vascular event, an episode of supraventricular tachycar-
dia, occurred in a patient with a history of mitral valve
prolapse and cardiac arrhythmias, who was randomised
to prucalopride 2 mg.125
Cardiovascular safety was also assessed as part of a
study conducted in a high-risk population. For this
study, 89 elderly patients residing in a nursing facility
(mean age 83 years) were randomised to prucalopride
(0.5, 1 or 2 mg) or placebo. Of the participants, 80% had
prior history of cardiovascular disease. There were no
differences in vital signs, laboratory results or ECG
parameters between groups. Moreover, there were no dif-
ferences in the incidence of prolonged QTc interval
between groups.132
Velusetrag (TD-5108). Velusetrag is a high-afﬁnity 5-
HT4 receptor agonist, which is being developed for the
treatment of chronic constipation.
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Pharmacokinetics and pharmacodynamics. The pharma-
cokinetics and pharmacodynamics of velusetrag are sum-
marised in Tables 2 and 3 respectively.
Clinical studies. Clinical studies with velusetrag have
focused on patients with chronic constipation. The few
trials that have been published have described signiﬁcant
improvements in bowel frequency and constipation-
related symptoms vs. placebo (Supplementary Table S7).
Safety and tolerability. In general, there were no SAEs
with velusetrag treatment; notable AEs were the predict-
able GI effects such as diarrhoea or altered bowel move-
ments. In the 401-patient Phase IIb trial, 12–15% of
patients developed diarrhoea on velusetrag relative to
placebo (1%).133 Of the three velusetrag doses tested,
15 mg provided the most favourable therapeutic index.
The 50-mg dose was associated with higher prevalence
of nausea, vomiting and headache than the other veluse-
trag doses and placebo.
An approximate 10 bpm increase in heart rate was
observed following administration of 15 mg velusetrag in
healthy volunteers and patients with chronic constipa-
tion.133 However, in the absence of a placebo control
group, this observation is difﬁcult to interpret. The signiﬁ-
cance of the single observations of palpitations (noted with
velusetrag at 30 mg) and asymptomatic junctional escape
rhythm (with 50 mg dose) noted in the pharmacodynamic
transit study134 is uncertain, considering the limited num-
ber of subjects. In ~540 healthy subjects or patients with
chronic constipation treated with velusetrag for up to
28 days, one patient with constipation experienced palpita-
tions in the placebo group and one healthy volunteer had
junctional escape rhythm following velusetrag at 70 mg.135
In vitro studies show that velusetrag (3 lM, 5-min
application, n = 3 cells) had no signiﬁcant effect on the
magnitude of hERG potassium tail currents recorded
from Chinese hamster ovary (CHO)-K1 cells expressing
hERG channels.55
Naronapride (ATI-7505). Naronapride is structurally
related to the chemical structure of cisapride, but devoid
of signiﬁcant afﬁnities for other 5-HT receptors or the
hERG channel.136 The drug is under evaluation for treat-
ment of upper and lower GI motility disorders, but only
limited data have been published.
Pharmacokinetics and pharmacodynamics. The pharma-
cokinetics and pharmacodynamics of naronapride are
summarised in Tables 2 and 3 respectively.
Clinical trials and indications/approvals. Naronapride
has been evaluated in Phase II trials in chronic constipa-
tion, GERD and FD. Naronapride (80 mg b.d.) demon-
strated signiﬁcant improvement over placebo in chronic
constipation.137 In the upper GI tract, early Phase II
studies indicated potential for reduction of reﬂux events
and FD symptoms.138
Safety. The cardiac safety of naronapride has been eval-
uated in a thorough QT study, which assesses the cardiac
safety of a drug vs. both placebo and a positive control
(e.g. moxiﬂoxacin), and has conﬁrmed a favourable
safety proﬁle at therapeutic or supratherapeutic doses.139
DISCUSSION
Patients with symptoms that are potentially attributable
to hypomotility of the GI tract constitute an important
part of clinical GI practice.1 These conditions are part of
a spectrum that ranges from functional dysphagia and
GERD, through FD and gastroparesis, to IBS-C and
chronic constipation. Prokinetic drugs are considered the
drugs of choice for the treatment of hypomotility disor-
ders, although the correlation between impaired motility
and symptoms is inconsistent.1
The 5-HT4 receptor, with its location on cholinergic
nerve endings of interneurons and motor neurons, has
been established as a valid target to enhance GI motility.
Mechanistic studies have conﬁrmed a stimulatory effect
of 5-HT4 receptor agonists on GI motor activity, and
clinical efﬁcacy in hypomotility disorders has been estab-
lished for a number of these drugs. Cisapride, as well as
tegaserod, saw broad clinical application after regulatory
approval (not in the EU for the latter drug),4, 5 but both
drugs were withdrawn (in the US), in part, because of
cardiovascular AEs.6–8, 41 The prevalence of cardiovascu-
lar AEs with both drugs was low and likely to fall below
the limit of detection in a clinical trial programme.
These events might seriously hamper the clinical
development of novel 5-HT4 receptor agonists for the
treatment of GI hypomotility disorders, especially when
taking into account the ability to establish cardiovascular
safety. However, several chemical classes of 5-HT4 recep-
tor agonists have been developed, and the selectivity of
different compounds for the 5-HT4 receptor over other
targets is highly variable between individual drugs and
drug classes. The mechanism through which cisapride
promotes cardiac arrhythmias is now clearly established
to be unrelated to 5-HT4 receptor agonism. The cardiac
risk associated with cisapride use is entirely attributable
to its afﬁnity for the hERG channel which results in QT
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prolongation, and is enhanced by concomitant use of
inhibitors of CYP, the principal pathway in cisapride
metabolism.7, 8, 41, 59, 60, 62–69 Hence, 5-HT4 receptor ag-
onists without afﬁnity for the hERG channel are devoid
of this particular arrhythmogenic risk. Another risk fac-
tor in the case of cisapride was its metabolism through
the CYP450 pathway, leading to increased plasma levels
when other drugs also metabolised via this same path-
way were taken at the same time. The mechanism
through which tegaserod use may be associated with
increased cardiovascular risk is not clearly established.
However, it has been suggested that the afﬁnity of tegas-
erod for the 5-HT1 or 5-HT2(b) receptors may underlie
these AEs.27, 92 This would implicate lack of such risk
for novel, highly-selective 5-HT4 receptor agonists.
The link between cardiovascular risk, the CYP450
metabolic pathway and lack of selectivity of previously
used 5-HT4 receptor agonists supports the development of
selective 5-HT4 receptor agonists for the treatment of GI
hypomotility disorders, as was the case with prucalopride
for chronic constipation.27 The recent EMEA approval of
prucalopride for the treatment of chronic constipation
conﬁrms that 5-HT4 receptor agonists are still considered
a valid therapeutic target at the regulatory level.1 Although
no link between 5-HT4 agonism and cardiovascular AEs
has been established, standards for establishing cardiovas-
cular safety for this class of drugs may still be elevated at
the regulatory level. Indeed, the cardiovascular safety pro-
ﬁle of prucalopride was assessed in great detail, both in vitro
and in the clinical trial programme.26, 38, 130–132
Although this review may be limited by incomplete
retrieval of relevant research, by bias in reporting such
research, and by inherent risk of bias at the study level, our
analysis of the literature has revealed a wealth of evidence
that 5-HT4 receptor agonists have clinical efﬁcacy in the
treatment of GI disorders and no evidence of cardiovascu-
lar safety concerns with selective 5-HT4 receptor agonists.
Nevertheless, caution is warranted as the number of
patients exposed to the newer 5-HT4 agonists is still rela-
tively low (number of exposed patients can be derived from
the Supplementary Tables for each drug), and adequate
post-marketing surveillance will help to further establish
the favourable cardiovascular risk proﬁle of these agents.
CONCLUSIONS
5-HT4 receptor agonists have clear-cut prokinetic effects in
the gut. These agonists differ in many aspects that are either
related or unrelated to their interaction with 5-HT4 recep-
tors. Differences that are unrelated to the 5-HT4 receptor,
such as afﬁnity at non-5-HT4 receptors, may inﬂuence the
agent's safety and overall beneﬁt–risk proﬁle. 5-HT4 recep-
tor-related differences have an impact on the agonists over-
all activity in a given tissue. Together, these differences
affect the therapeutic potential for the treatment of GI
motility disorders. Based on available evidence, a highly
selective 5-HT4 receptor agonist, such as prucalopride, may
offer improved efﬁcacy and safety to treat patients with
impaired GI motility, such as severe chronic constipation.
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